Download PDF
Semin Hear 2013; 34(01): 027-036
DOI: 10.1055/s-0032-1333149
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Early Diagnosis and Management of Hearing Loss in Medically Fragile Children

Brian J. Fligor
1   Boston Children's Hospital
2   Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
29 January 2013 (online)

    Permissions and Reprints

Abstract

Newborns and young children with serious medical problems pose a challenge to the success of universal newborn hearing screening. The need for ototoxic medications to rescue the critically ill child increases the risk for hearing loss that is already high due to the underlying disease. Congenital cytomegalovirus infection, aggressive life support including extracorporeal membrane oxygenation, and platinum-based chemotherapy to treat childhood cancer are cause to closely monitor hearing once health care attention turns from rescue to recovery. Algorithms for surveillance for hearing loss help reduce the time delay between the adventitious onset of hearing loss and the diagnosis and intervention. Understanding the relative risk for hearing loss for the individual child can help clinicians counsel families regarding the anticipated need for audiologic intervention. Assuring adequate hearing habilitation includes objective verification of audiologic interventions, as this young and ill patient population often cannot communicate the appropriateness of hearing aid settings. The use of FM systems is quite often necessary given the steeply sloping configuration of ototoxic hearing loss, and candidacy for cochlear implant may be complicated, but certainly not contraindicated, in children with complex medical histories.

Keywords

CMV - ECMO - aminoglycosides - chemotherapy - ototoxicity - UNHS
 

  • References

  • 1 American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120: 898-921
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention (CDC). 2008. Summary of 2006 national EHDI data. Available at: http://www.cdc.gov/ncbddd/ehdi/data.html . Accessed April 22, 2009
    PubMedGoogle Scholar
  • 3 Centers for Disease Control and Prevention (CDC). 2012. Summary of 2009 National CDC EHDI Data. Available at: http://www.cdc.gov/ncbddd/hearingloss/2009-Data/2009_EHDI_HSFS_Summary_508_OK.pdf . Accessed May 4, 2012
    PubMedGoogle Scholar
  • 4 Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday and today. Arch Otolaryngol Head Neck Surg 1999; 125: 517-521
    CrossrefPubMedGoogle Scholar
  • 5 Fligor BJ, Neault MW, Mullen CH, Feldman HA, Jones DT. Factors associated with sensorineural hearing loss among survivors of extracorporeal membrane oxygenation therapy. Pediatrics 2005; 115: 1519-1528
    CrossrefPubMedGoogle Scholar
  • 6 Henderson D, Bielefeld EC, Harris KC, Hu BH. The role of oxidative stress in noise-induced hearing loss. Ear Hear 2006; 27: 1-19
    CrossrefPubMedGoogle Scholar
  • 7 Wang J, Puel JL, Bobbin R. Mechanisms of toxicity in the cochlea. In: Campbell KCM, , ed. Pharmacology and Ototoxicity for Audiologists. Clifton Park, NY: Thomson Delmar Learning; 2007: 70-85
    Google Scholar
  • 8 Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991; 13: 315-329
    CrossrefPubMedGoogle Scholar
  • 9 Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130: 624-630
    PubMedGoogle Scholar
  • 10 Dahle AJ, Fowler KB, Wright JD, Boppana SB, Britt WJ, Pass RF. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol 2000; 11: 283-290
    PubMedGoogle Scholar
  • 11 Schleiss MR. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis 2005; 16: 50-59
    CrossrefPubMedGoogle Scholar
  • 12 Extracorporeal Life Support Organization; ECMO Registry of the Extracorporeal Life Support Organization (ELSO). Ann Arbor, MI: Extracorporeal Life Support Organization; 2002
    Google Scholar
  • 13 Graziani LJ, Gringlas M, Baumgart S. Cerebrovascular complications and neurodevelopmental sequelae of neonatal ECMO. Clin Perinatol 1997; 24: 655-675
    CrossrefPubMedGoogle Scholar
  • 14 Cheung PY, Robertson CM. Sensorineural hearing loss in survivors of neonatal extracorporeal membrane oxygenation. Pediatr Rehabil 1997; 1: 127-130
    PubMedGoogle Scholar
  • 15 Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596
    CrossrefPubMedGoogle Scholar
  • 16 Bertolini P, Lassalle M, Mercier G , et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655
    CrossrefPubMedGoogle Scholar
  • 17 Frazier AL, Weldon C, Amatruda J. Fetal and neonatal germ cell tumors. Semin Fetal Neonatal Med 2012; 17: 222-230
    CrossrefPubMedGoogle Scholar
  • 18 Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-2451
    CrossrefPubMedGoogle Scholar
  • 19 Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52: 387-391
    CrossrefPubMedGoogle Scholar
  • 20 Hua C, Bass JK, Khan R, Kun LE, Merchant TE. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 2008; 72: 892-899
    CrossrefPubMedGoogle Scholar
  • 21 Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2009; 73: 779-788
    CrossrefPubMedGoogle Scholar
  • 22 Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28: 1788-1795
    CrossrefPubMedGoogle Scholar
  • 23 Bindu LH, Reddy PP. Genetics of aminoglycoside-induced and prelingual non-syndromic mitochondrial hearing impairment: a review. Int J Audiol 2008; 47: 702-707
    CrossrefPubMedGoogle Scholar
  • 24 Ross CJ, Katzov-Eckert H, Dubé MP , et al; CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349
    CrossrefPubMedGoogle Scholar
  • 25 Brock PR, Knight KR, Freyer DR , et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 2012; 30: 2408-2417
    CrossrefPubMedGoogle Scholar
  • 26 Katzenstein HM, Chang KW, Krailo M , et al; Children's Oncology Group. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009; 115: 5828-5835
    CrossrefPubMedGoogle Scholar
  • 27 Sininger YS, Grimes A, Christensen E. Auditory development in early amplified children: factors influencing auditory-based communication outcomes in children with hearing loss. Ear Hear 2010; 31: 166-185
    CrossrefPubMedGoogle Scholar